These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 17665440)

  • 41. Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases.
    Lu TY; Jónsdóttir T; van Vollenhoven RF; Isenberg DA
    Ann Rheum Dis; 2008 Oct; 67(10):1493-4. PubMed ID: 18791057
    [No Abstract]   [Full Text] [Related]  

  • 42. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
    Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
    Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long term treatment of rheumatoid arthritis with rituximab.
    Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
    Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of rituximab in patients with systemic lupus erythematosus: an update.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Galarza-Maldonado C; Sandoval-Cruz M; Zamudio-Huerta L; López-Colombo A; Cervera R
    Autoimmun Rev; 2009 Feb; 8(4):343-8. PubMed ID: 19036350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.
    Mease PJ
    J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of rituximab on resistant SLE disease including lung involvement.
    Reynolds JA; Toescu V; Yee CS; Prabu A; Situnayake D; Gordon C
    Lupus; 2009 Jan; 18(1):67-73. PubMed ID: 19074171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progression of classic Kaposi's sarcoma with rituximab.
    Clifford KS; Demierre MF
    J Am Acad Dermatol; 2005 Jul; 53(1):155-7. PubMed ID: 15965441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. B cell depletion therapy in rheumatic disease.
    Edwards JC; Cambridge G; Leandro MJ
    Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):915-28. PubMed ID: 16980214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rituximab, B-lymphocyte depletion, and beta-cell function.
    Nagafuchi S; Katsuta H; Anzai K
    N Engl J Med; 2010 Feb; 362(8):761; author reply 761. PubMed ID: 20181981
    [No Abstract]   [Full Text] [Related]  

  • 51. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
    Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
    Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
    [TBL] [Abstract][Full Text] [Related]  

  • 52. B cell targeted therapies: safety considerations.
    Kavanaugh AF
    J Rheumatol Suppl; 2006 May; 77():18-23. PubMed ID: 16652441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clonal expansion of B-cells in human systemic lupus erythematosus: evidence from studies before and after therapeutic B-cell depletion.
    Sfikakis PP; Karali V; Lilakos K; Georgiou G; Panayiotidis P
    Clin Immunol; 2009 Jul; 132(1):19-31. PubMed ID: 19345151
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation.
    Dello Strologo L; Guzzo I; Laurenzi C; Vivarelli M; Parodi A; Barbano G; Camilla R; Scozzola F; Amore A; Ginevri F; Murer L
    Transplantation; 2009 Aug; 88(3):417-20. PubMed ID: 19667947
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New approaches of B-cell-directed therapy: beyond rituximab.
    Dörner T; Burmester GR
    Curr Opin Rheumatol; 2008 May; 20(3):263-8. PubMed ID: 18388516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.
    Steinmetz OM; Lange-Hüsken F; Turner JE; Vernauer A; Helmchen U; Stahl RA; Thaiss F; Panzer U
    Transplantation; 2007 Oct; 84(7):842-50. PubMed ID: 17984836
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.
    Tesfa D; Ajeganova S; Hägglund H; Sander B; Fadeel B; Hafström I; Palmblad J
    Arthritis Rheum; 2011 Aug; 63(8):2209-14. PubMed ID: 21560117
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.
    Owczarczyk K; Hellmann M; Fliedner G; Röhrs T; Maizus K; Passon D; Hallek M; Rubbert A
    Ann Rheum Dis; 2008 Nov; 67(11):1648-9. PubMed ID: 18854518
    [No Abstract]   [Full Text] [Related]  

  • 59. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
    Renato GM
    Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
    [TBL] [Abstract][Full Text] [Related]  

  • 60. B cell monitoring of transplant patients treated with anti-CD20.
    Abdallah KO; Prak ET
    Clin Transpl; 2006; ():427-37. PubMed ID: 18365400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.